Type 2 diabetes is a major cause of increasing mortality incurring vast expenditures. Direct costs of type 2 diabetes account for $1.31 trillion and additional indirect costs account for 35% of the total burden [1]. Type 2 diabetes is one of five leading causes of premature death in high-income countries [2]. In 2017, around 415 million adults suffered from Type 2 diabetes [2]. Estimates suggest that over the next decade, 642 million adults will suffer from type 2 diabetes [2]. Moreover, type 2 diabetes, thus far diagnosed among adults, is now expanding to adolescents and children, making it THE epidemic of the 21 st century [3]. So far, all interventions to maintain Glycemic control achieved sub-optimal outcomes [3-7]. Lack of Glycemic control leads to progress of type 2 diabetes resulting in a range of health complications, morbidity and disability [2]. Tremendous efforts to halt the expansion of type 2 diabetes involved: behavior-modification programs, pharmacological interventions and educational interventions. Whereas policy makers viewed these efforts as promising means to affect modifiable determinants of type 2 diabetes